Nevertheless, other studies have demonstrated that tumor-derived EVs can inhibit the proliferation of CD8+ T cells by lowering the levels of IL-2 or inducing CD8+ T cell apoptosis through mechanisms such as Galectin 9 and the FasL-TRAIL pathway (219, 220). This evidence concerns the gene CD8A and neoplasm.